Latest Italy News

Memphasys Limited has extended the repayment terms of its convertible notes with major shareholder Peters Investments to mid-2026, reinforcing financial flexibility amid ongoing commercial progress.

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.

Altamin Limited has completed a $1.003 million placement, bolstering its financial position to progress key projects in Italy amid ongoing permitting and partnership efforts.

Memphasys has inked a five-year supply agreement with Italy’s Centro Fertilita Assistita, marking its first major European contract and setting the stage for broader adoption of its Felix™ sperm isolation system.

BetMakers Technology Group has secured a multi-year deal with Stake.com to provide its comprehensive RaceOdds+ wagering platform, supporting Stake’s ambitious global horse racing growth plans.

Prescient Therapeutics has secured European authorization to initiate a Phase 2a clinical trial of its novel cancer drug PTX-100 for relapsed/refractory Cutaneous T-cell Lymphoma, enabling trial site activation in Italy.

Altamin Limited has locked in $753,000 through a share placement to cover part of its entitlement offer shortfall, attracting sophisticated investors from the UK and Australia.

Keybridge Capital Limited is navigating a complex recovery with new board leadership, partial loan repayments, and favorable court rulings against former executives. The company is steadily addressing legacy financial and legal challenges.

Altamin Limited has appointed GBA Capital as lead manager to place shortfall shares from its recent entitlement offer, offering broker options as part of the arrangement. This move aims to bolster support for its critical minerals projects in Italy while engaging new and existing investors.

ADX Energy has raised A$3.5 million through a placement to fund key gas exploration projects in Austria and Italy, alongside plans for a strategic dual listing in Oslo.

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

Altamin Limited has advanced its geothermal lithium ambitions with a significant A$3.62 million grant from the Italian government, alongside strategic board changes and a $4.39 million capital raise.